218cda38-ec89-4e23-849b-93f1b5bd0655
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 66.8501026694045
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
- UV_RESPONSE_DN+0.390
- ANGIOGENESIS+0.380
- INTERFERON_ALPHA_RESPONSE+0.380
- PANCREAS_BETA_CELLS+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
- G2M_CHECKPOINT+0.370
- E2F_TARGETS+0.360
- INFLAMMATORY_RESPONSE+0.280
- KRAS_SIGNALING_UP+0.270
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.470
- FATTY_ACID_METABOLISM-0.360
- ADIPOGENESIS-0.350
- PEROXISOME-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- HEME_METABOLISM-0.250
- XENOBIOTIC_METABOLISM-0.240
- P53_PATHWAY-0.210
- PI3K_AKT_MTOR_SIGNALING-0.200
- BILE_ACID_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A4SE-01A-11R-A266-07 | — | E | 0.838 |
| 2 | c56e13bb-f1b0-4ee3-85c1-807c7c3bcef9 | — | — | 0.818 |
| 3 | SRR4296078 | — | cohortSQ1 | 0.802 |
| 4 | SRR8613802 | — | D | 0.797 |
| 5 | f3781318-56be-4a43-b72d-a6bb65ef9a88 | — | — | 0.788 |
| 6 | SRR17866841 | — | — | 0.784 |
| 7 | SRR8518161 | — | E | 0.784 |
| 8 | SRR27320698 | — | — | 0.782 |
| 9 | SRR8518214 | — | D | 0.782 |
| 10 | ERR2278875 | — | — | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.610 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |